Neopterin as a potential biomarker in neuropsychiatry

Shilov, Yu E; Miroshnichenko, I. I.

doi:10.17116/jnevro2020120101125

Cited by 1 publication

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neopterin is a catabolic product of guanosine triphosphate, a purine nucleotide. Recently it was argued that an increase in neopterin levels in biological fluids (e.g., serum, cerebrospinal fluid, or urine) strongly correlates with various neuropsychiatric disorders [ 16 ]. Uric acid is a molecule produced by the metabolism of purines: a study by Chen et al associated the reduction in serum uric acid levels with a higher suicide rate in patients with major depressive disorder [ 17 ].…”

Section: Introductionmentioning

confidence: 99%

“…Nonetheless, it has never been assessed in the blood of patients with FND. Finally, creatinine, neopterin and uric acid have been recently associated with several neuropsychiatric conditions [15][16][17] but, again, they have never been studied in FND. Creatinine is an amino acid derivative, produced by the liver and used in the muscles to produce ATP for the purpose of muscle contraction.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Glutamatergic dysfunction, neuroplasticity, and redox status in the peripheral blood of patients with motor conversion disorders (functional movement disorders): a first step towards potential biomarkers discovery

Demartini,

Nisticò,

Benayoun

et al. 2023

Transl Psychiatry

View full text Add to dashboard Cite

Functional movement disorders (FMD) are characterized by the presence of neurological symptoms that cannot be explained by typical neurological diseases or other medical conditions. First evidence showed that, compared to healthy controls (CTR), FMD patients presented increased levels of glutamate+glutamine in the anterior cingulate cortex/medial prefrontal cortex, and decreased levels of glutamate in the cerebrospinal fluid, suggesting that a glutamatergic dysfunction might play a role in FMD pathophysiology. In this study, 12 FMD patients and 20 CTR were recruited and underwent venous blood sampling and urine collection: levels of glutamate, BDNF, dopamine, oxidative stress, creatinine, neopterin, and uric acid were analyzed. Participants also underwent a psychometric assessment investigating depression, anxiety, and alexithymia. We found that levels of glutamate, BDNF, and dopamine were significantly lower in the blood of FMD patients than CTR. Glutamate and dopamine levels were positively associated with levels of alexithymia. Our findings give further evidence that glutamatergic dysfunction might be involved in the pathophysiology of FMD, possibly representing a biomarker of disease; moreover, since glutamatergic and dopaminergic systems are closely interconnected, our results might have a relevance in terms of treatment options for FMD patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%